Immunocore Holdings (IMCR) Free Cash Flow (2021 - 2026)

Immunocore Holdings (IMCR) has reported Free Cash Flow for 6 consecutive years, with -$15.6 million the latest figure, recorded in Q1 2026.

• Quarterly Free Cash Flow fell 11454.74% year-over-year to -$15.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$30.7 million (down 218.06% YoY) and the FY2025 annual result came in at -$15.1 million, down 172.06% from the prior year.
• Free Cash Flow advanced to -$15.6 million in Q1 2026 per IMCR's latest filing, from -$35.5 million in the prior quarter.
• Over the last five years, Free Cash Flow for IMCR reached as high as $25.5 million in Q2 2025 and fell as low as -$35.5 million in Q4 2025.
• A 5-year average of $301298.4 and a median of $3.1 million in 2022 frame the typical range for Free Cash Flow.
• Annual changes were most pronounced in 2022 — Free Cash Flow jumped 115.35% — and 2026, when it plunged 11454.74%.
• Year by year, Free Cash Flow stood at $6.0 million in 2022, then plunged by 409.25% to -$18.6 million in 2023, then gained by 5.47% to -$17.5 million in 2024, then sank by 102.65% to -$35.5 million in 2025, then surged by 56.22% to -$15.6 million in 2026.
• According to Business Quant data, Free Cash Flow over the past three periods registered -$15.6 million, -$35.5 million, and -$5.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.